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According to World Health Organization (WHO), antimicrobial 
resistance is one of the major global health issues to track in 
2021. As the efficiency of current antibiotics have gradually 
been declining for several decades due to the deteriorating 
resistance status, the demands to develop new potential 
antimicrobial drugs have increased rapidly. Bacterial virulence 
factors are molecules that enhances the probability of the 
pathogen to cause disease in a host. With antivirulence drugs, 
bacteria are not killed, but specifically disarmed by neutralizing 
their virulence factors, thus exposing pathogens to the influence 
of immunological defense mechanisms. In use of pathogen 
specific antivirulence drugs, the selective pressure for resistance 
is believed to be reduced since the drugs don’t directly have an 
effect on bacterial viability. 
 
Exotoxins are an extensive group of bacterial proteins, which 
can damage the host cells by disrupting physiological cellular 
functions, or directly destroy host cells, e.g. via cell lysis. 
Exotoxins have a significant role in bacterial pathogenicity and 
in some infectious diseases, e.g. cholera, tetanus and botulism, 
bacterial exotoxins act as the primary disease-causing virulence 
factor and are therefore ideal targets for antivirulence drugs. 
 
In this review article, we focus on drug modalities, which target 
bacterial exotoxins. We describe how the different drug 
modalities work and review the key pre-clinical and clinical trial 
data that has led to the approval of currently used exotoxin-
targeted drugs: Raxibacumab (Abthrax®), obiltoxaximab 
(Anthim®) and bezlotoxumab (Zinplava®). We also go through 
the advantages and disadvantages of these modalities and 
highlight the recent outcomes from preclinical and clinical trials 
of potential exotoxin-targeting drug molecules. The manuscript 
of this review article has been sent to be peer reviewed and 
published in ACS Infectious Diseases. 
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ABSTRACT  
The paradigm of antivirulence therapy dictates that bacterial pathogens are specifically disarmed but 
not killed by neutralizing their virulence factors. Clearance of the invading pathogen by the immune 
system is promoted. As compared to traditional antibiotics, the  pathogen-selective antivirulence 
drugs hold promise to minimize collateral damage to the beneficial microbiome. Also, selective 
pressure for resistance is expected to be lower because bacterial viability is not directly affected. 
Antivirulence drugs are being developed for stand-alone prophylactic and therapeutic treatments, but 
also for combinatorial use with antibiotics. This review focuses on drug modalities, which target 
exotoxins - a ubiquitous group of secreted or released-upon-lysis bacterial proteins. Exotoxins have 
a significant and sometimes the primary role as the disease-causing virulence factor. We describe the 
key pre-clinical and clinical trial data that has led to the approval of currently used exotoxin-targeted 
drugs, naimly the monoclonal antibodies Bezlotoxumab (toxin B/TcdB, Clostridioides difficile), 
Raxibacumab (anthrax toxin, Bacillus anthracis) and Obiltoxaximab (anthrax toxin, Bacillus 
anthracis),  but also to challenges with some of the promising leads, e.g. ASN-100 (a-toxin and 5 
leukocidins, Staphylococcus aureus) and Shigamabs (Shiga toxins 1 and 2, Escherichia coli). We 
also highlight the recent developments in pre-clinical research sector to develop exotoxin-targeted 
drug modalities, i.e. monoclonal antibodies, antibody fragments, antibody mimetics, receptor analogs 
and neutralizing scaffolds, dominant negative mutants and small molecules. We discuss how these 





























Bacterial virulence, i.e. ability of the bacterium to infect the host and to cause damage, is a 
multifactorial process involving components both from the invading bacterium and the host.   The 
pathogen-host interplay culminates, typically in a bacterium-specific manner, into development of 
disease symptoms ranging from acute life-threatening conditions to chronic persistence that variably 
burdens the host. As defined by Diard and Hardt 1, bacterial virulence factor “is any genetic attribute 
that increases the chance to cause disease in a host”. It is experimentally defined by the so-called 
molecular Koch’s postulates: i) a virulence factor is expressed by the disease-causing strains, ii) 
deletion of the virulence factor reduces the risk of damage to the host, and iii) complementation of 
the virulence factor deletion mutant should restore the virulence of the pathogen.   
 
The paradigm of antivirulence therapy, as coined in the seminal review article in 2007 2, dictates that 
bacterial pathogens are specifically disarmed but not killed by neutralizing their virulence factors. 
Clearance of the invading pathogen by the immune system is promoted. Although the antivirulence 
therapy is frequently debated as a new and emerging approach, historically it precedes the use of 
antibiotics. The first Nobel Prize in Medicine in 1901 was awarded to Emil von Behring for his work 
on serum therapy, especially on its application against diphtheria with diphtheria toxin-neutralizing 
horse antiserum. To some extent, these virulence factor-neutralizing polyvalent antiserum-based 
therapeutics are still being used today, e.g. Diphtheria Anti-Toxin (DAT) 3, Botulism Antitoxin 
Heptavalent [A,B,C,D,E,F,G]-[EQUINE] (BAT) 4 and Botulism Immune Globulin Intravenous 
(BIG-IV / BabyBIG) 5. In addition, intravenous immunoglobulin (IVIG) preparations that are 
composed of polyvalent immunoglobulins from pooled plasma samples of thousands of individuals 
are being developed and used to treat severe diseases such as necrotising soft tissue infections, e.g. 6 
[NCT01790698, NCT02111161]. However, decades of basic research using various in vitro assays, 
cell and tissue culture models and animal experimentation have created an in-depth view on bacterial 
virulence factors 1. It is this molecular and physiological knowledge that is driving the development 
of next generation targeted antivirulence therapies involving different modalities, not only antibodies.  
As already discussed in the seminal review article in 2007 2, collateral damage to the beneficial 
microbiome is expected to be minimal along with the reduced probability to develop resistance. 
Antivirulence therapeutics hold promise to tackle the ever increasing problem of antimicrobial 
resistance, either via the combinatorial use with antibiotics or as stand-alone prophylactic or 
therapeutic drugs.  
Exotoxins - a ubiquitous group of secreted or released-upon-lysis bacterial proteins (Figure 1) - have 
a significant and sometimes the primary role as the disease-causing virulence factor, e.g. in whooping 
cough, cholera, diphtheria, tetanus, botulism, anthrax and toxic shock syndrome.  
Exotoxins are therefore ideal targets for antivirulence drugs. Exotoxins can be classified into three 
types based on their mode of action - Type I) superantigens, Type II) membrane-disrupting toxins, 
and Type III) intracellular-targeting toxins. Superantigens, such as toxic shock syndrome toxin-1 
(TSST-1) of Staphylococcus aureus 7, bind simultaneously to major histocompatibility complex 
(MHC) class II and T-cell  receptor (TCR) molecules on host antigen-presenting cells (APCs) and T-
lymphocytes, respectively. Docking of TSST-1 to MHCII/TCR hyperactivates T-cells leading to 
systemic release of inflammatory cytokines and development of potentially fatal toxic shock 
syndrome 7. Membrane-disrupting toxins, come in three different flavors. The pore-forming toxins, 
such as the a-toxin (Hla, Hemolysin-a) of S. aureus 7, comprise by far the largest group. When a-
toxin of S. aureus binds on the host cell surface, it oligomerizes and attacks the cell membrane by 
extrusion of a b-barrel through the lipid bilayer to form a hydrophilic transmembrane channel and 
cell death via osmotic lysis 7. Membrane-disrupting toxins can also act by directly modifying the 
membrane lipids or by displaying detergent-like functions. The b-toxin (b-hemolysin) of S. aureus 7, 
for instance, cleaves sphingomyelin, the most abundant eukaryotic membrane sphingolipid. The 
amphipathic peptides known as phenol-soluble modulins, such as 𝛿-toxin of  S. aureus 7, integrate 
into the host cell plasma membrane to cause membrane instability. Intracellular-targeting toxins are 
diverse group of virulence factors formed of either covalently or non-covalently bound A and B 
subunits. The A subunit possesses the enzymatic activity, and the B subunit mediates the cell entry. 
Pertussis toxin (PTX), as an example, is the major virulence factor of Bordetella pertussis 8, secreted 
from the bacteria via the Sec-pathway and the Ptl type IV secretion system 9. PTX is composed of 
five non-covalently bound subunits (PtxS1-S5), which are arranged in an AB5-topology 10, 11. The 
B5-oligomer is formed by the PtxS2-S5 (PtxS2, PtxS3, PtxS5 and 2 copies of PtxS4) 10, 11 and 
mediates binding of the AB5 holotoxin on the host cell surface in a carbohydrate-dependent manner 
11. Endocytosis-mediated cell entry is followed by retrograde trafficking into the endoplasmic 
reticulum (ER) 12, dissociation of the B5-assembly from the PtxS1-subunit 
13, which belongs to the 
family of ADP-ribosyltransferases (ARTs) 14, and ER-associated degradation (ERAD) pathway-
dependent transport of PtxS1 into the cytosol 15. In the cytosol, PtxS1 ADP-ribosylates a single C-
terminal cysteine residue in inhibitory α-subunits of most heterotrimeric (α) G protein superfamily 
members, such as Gαi, Gαo, and Gαt 16-18. The resulting bulky ADP-ribose modification disrupts 
inhibitory α-subunit interaction with G protein-coupled receptors (GPCRs), preventing formation of 
the Gα-GPCR complex and thereby perturbing GPCR agonist-induced signaling 19. Other 
intracellular-targeting toxins follow more or less the same principles as PTX in how they interact with 
the host cell, i.e. docking into the cell surface receptor, endocytosis, intracellular maturation and 
execution of the cytosolic activity, mostly involving modification of a specific cytosolic host protein. 
However, topologies of the AB-assembly vary, e.g. AB (diphtheria toxin), AB5 (pertussis toxin) and 
A2B5 (typhoid toxin), some toxins such as diphtheria toxin gain access into the cytosol from the 
endosome and an array of enzyme activities in addition to protein ADP-ribosylation are executed in 
the cytosol (Figure 1).  
 
Antivirulence drugs are being developed and used to prevent all four main steps in the functional 
pathway of exotoxins - secretion, cell surface binding, intracellular maturation and cytosolic effector 
functions (Figure 1). There is active research to develop inhibitors targeting the Sec-pathway 
responsible for the secretion of majority of bacterial proteins, in particular the bacteria-specific SecA 
protein, e.g. 20. Also, other bacterial secretion systems such as the type III secretion system (T3SS), 
which is responsible for the delivery of effector proteins directly into the host cell cytosol involving 
a needle-like apparatus, is targeted in drug development projects, e.g. 21. Although T3SS does not 
classify as a bona fide exotoxin-delivery apparatus, it provides a proof-of-principle case on the 
potential of secretion inhibitors as drug leads. Phase II trial (NCT02696902) was just recently finished 
on the use of MEDI3902 to treat pneumonia cause by Pseudomonas aeruginosa. MEDI3902 is a 
human monoclonal antibody (mAb) that has been engineered to bind both the PcrV T3SS needle tip 
protein and the bacterial Psl exopolysaccharide 22. Phase II trial (NCT01695343) has also been 
conducted in cystic fibrosis on a different PcrV-targeting human antibody fragment, the anti-PcrV 
PEGylated-Fab KB001A 23. A modest forced expiratory volume in 1 sec (FEV1) and reduction in 
sputum IL-8 were recorded, but the overall efficacy of KB001A in cystic fibrosis was weak 23. 
Another active line of research is focused on targeting host cell components, in particular proteins, 
that are important in the functional pathway of exotoxins. For instance, small molecules have been 
identified, which affect the endosomal maturation 24, retrograde trafficking 25, 26, intracellular 
activatory proteolytic processing 27, 28  and  intracellular chaperon-assisted activatory folding 29. 
However, a rationally designed host molecule-targeted drug that affects the functional pathway of 
exotoxins has yet to reach clinical trials.    
This review is focused on drug modalities, which specifically target exotoxins after the secretion or 
release-upon-lysis, i.e. antibodies, antibody fragments, antibody mimetics, receptor analogs and 
neutralizing scaffolds, dominant negative mutants and small molecules. We describe how these 
modalities work and highlight their advantages and disadvantages as antibiotic alternatives. Each 
modality is described with examples. We also provide a resource, i.e. primary research articles 
published on exotoxin-targeted drug modalities in the past 5 years (Suppl. Table 1), which we hope 
helps the reader to navigate in this rapidly expanding field of research. The review starts by 
description of the key pre-clinical and clinical trial data that has led to the approval of currently used 
exotoxin-targeted drugs. 
 
DRUGGABLE STEP I - CELL SURFACE BINDING  
Cell surface binding involving recognition of specific receptors is a necessary functional step for 
exotoxins. Many exotoxins such as superantigens and membrane-disrupting toxins also execute their 
effector functions at that particular cellular localization (Figure 1). A multitude of different drug 
modalities, including most of the currently FDA-approved and clinical trial drugs (Table 1, Figure 
2), target this step of the functional pathway of exotoxins.   
 
MONOCLONAL ANTIBODIES  
Monoclonal antibodies (mAbs) have several advantages in exotoxin-targeting such as high 
specificity, long in vivo half-life in circulation and good tolerability. In addition, mAbs do not merely 
act as passive extotoxin-neutralizing binders, but they also may execute beneficial Fc-fragment-
mediated functions such as complement interactions and phagocytosis of exotoxin-mAb complexes. 
Antibody engineering technologies help in the design of enhanced versions, e.g. in affinity and 
immunogenicity also involving the possibility to combine two targeting specificities into a single 
product, i.e. the so-called bispecific antibodies. Tissue penetration is a drawback of these relatively 
large molecules (IgG, ~150 kDa). 30 The exotoxin-neutralizing mAbs are powerful prophylactic 
drugs, although vast amount of clinical and pre-clinical data also supports their post-diagnostic 
therapeutic use. As for now, all the clinically used exotoxin-targeted drugs are mAbs.    
 
Raxibacumab (Abthrax®) and Obiltoxaximab (Anthim®) 
Anthrax is a rare, but potentially lethal disease caused by rod-shaped, Gram-positive, spore-forming 
bacterium Bacillus anthracis. Inhalational anthrax drew global attention after the 2001 bioterrorist 
attacks in the USA, which resulted in eleven confirmed cases of inhalational anthrax and five 
fatalities. The pathogenesis of inhalational anthrax is driven by the tripartite anthrax toxin complex 
31.  The three different subunits  - protective antigen (PA), lethal factor (LF), and edema factor (EF) 
- come together in binary combinations to form the lethal toxin (LT, PA+LF) and the edema toxin 
(ET, PA+EF). The PA recognizes specific receptors on the host cell surface, which leads to PA 
oligomerization, endocytosis of lethal toxin- and edema toxin-receptor complex, and release of LF 
and EF to the cytosol from the endosomal compartment 31. The LF is a zinc metalloproteinase that 
inactivates mitogen-activated protein kinase-kinases (MAPKK), and EF is a calmodulin- and 
calcium-dependent adenylate cyclase that increases the level of intracellular cyclic adenosine 
monophosphate (cAMP) 31.   
 
Obiltoxaximab is a chimeric PA-recognizing mAb, which has been engineered for higher affinity and 
for lower immunogenicity 32,  building on the early work on mouse anthrax toxin-neutralizing 
antibodies 33 and mAb-PA interaction affinity enhancing mutations (1H variant) 34. It is known at 
atomic resolution, in particular based on the work on its parental murine forms, that obiltoxaximab 
recognizes the receptor-binding region of PA 35 and thereby blocks PA-host cell receptor interactions. 
Raxibacumab is a fully human mAb binding to the PA, and acts in analogy to obiltoxaximab 36. 
Obiltoxaximab was approved by FDA in March 2016. Raxibacumab got its FDA-approval in 
December 2012 and it was developed under the Project BioShield Act, which was launched by the 
US government in 2004. Obiltoxaximab has  been shown to be well-tolerated among healthy 
volunteers in phase I trials and the most common adverse events included upper respiratory tract 
infections and hypersensitivity reactions 37. The safety, tolerability and pharmacokinetics of 
raxibacumab in humans were evaluated with healthy volunteers in four sub-studies performed by 
Human Genome Sciences 36, 38. These studies concluded that raxibacumab is safe, well-tolerated, and 
bioavailable after single intramuscular or intravenous dose 36, 38. Most adverse events were mild to 
moderate in severity and did not significantly differ from placebo 36, 38. Both drugs are indicated in 
adult and pediatric patients for the treatment of inhalational anthrax in combination with appropriate 
antibiotics and for prophylaxis of inhalational anthrax when alternative options are not available or 
are not appropriate. The recommended method of administration is intravenous infusion and the 
patients should be premedicated with oral or intravenous diphenhydramine to reduce the risk of 
infusion reactions [package inserts - Abthrax® (Raxibacumab), Rockville, MD, Human Genome 
Sciences, Inc, 2012; Anthim® (Obiltoxaximab), Pine Brook, NJ, Elusys Therapeutics, Inc, 2016]. 
 
The efficacy of Raxibacumab and Obiltoxaximab has been evaluated with animal experimentation 
utilizing rats, rabbits, dogs and macaques under the FDA Animal Rule. The main reason is that the 
nature of anthrax disease did not ethically justify human challenge studies. Initial therapeutic studies 
conducted in rats showed that raxibacumab increased survival when administered within 6 hours after 
a 24 hour toxin infusion 39. Survival rate was lower in rats that received raxibacumab at 9 or 12 hours, 
and  the survival rate also decreased with lower doses of raxibacumab 39. Rats that received a 
prophylactic dosage of raxibacumab 24 hours prior to toxin infusion had a survival rate of 100% 
whereas all rats in the placebo group died 36. In a study conducted with rabbits, animals receiving 
intravenous infusion of obiltoxaximab prior to exposure to anthrax spores had a survival 
rate of 100% whereas all saline-treated animals in control group died 32. Rabbits that 
received obiltoxaximab 24 hours after the exposure had a survival rate of 80%, and when 
obiltoxaximab was given at 36h the survival rate decreased to 50% 32. In the macaque mode, both 
raxibacumab and obiltoxaximab increased survival rates and the increase was dose-dependent 36, 40, 
41.  
 
Combinatorial therapeutic use with antibiotics, supportive care and anthrax toxin vaccination has also 
been studied by animal experimentation and clinical trials. The data in rabbits indicates that 
combining raxibacumab to levofloxacin improves survival compared to levofloxacin therapy alone 
42. Rabbit studies also support the use of obiltoxaximab-doxycycline combination 43.  In studies with 
canine model of anthrax toxin-associated shock it was shown that combination of hemodynamic 
support, i.e. titrated normal saline and norepinephrine infusions, and raxibacumab significantly 
improved survival compared to hemodynamic support alone 44. Survival benefit of combination 
therapy was associated with increased diuresis, improved blood pressure and reduced demand on 
vasopressors and oxygenation 44.   The FDA-approved anthrax vaccine, anthrax vaccine absorbed 
(AVA), is mainly composed of adsorbed PA. A concern arose that in the case of postexposure 
prophylaxis with combination of AVA and raxibacumab, the AVA immunogenity could be decreased 
due to toxin-neutralizing activity of raxibacumab. However, in a recent open-label, randomized, 
multicenter study it was concluded that co-administrating raxibacumab with AVA does not 
significantly reduce immunogenicity of AVA 45. There are currently two phase IV clinical trials with 
an objective to evaluate clinical benefit, safety and pharmacokinetics in patients treated with 
raxibacumab (NCT02177721) or obiltoxaximab (NCT03088111).  
 
 
Bezlotoxumab (Zinplava®)  
Clostridioides difficile infection (CDI) is the most common and costly cause of infectious diarrhea 
among hospitalized patients. It is caused by an anaerobic, Gram-positive, spore-forming, toxigenic 
bacterium and the disease usually follows antibiotic treatment due to dysbiosis of gut microbiota. The 
severity of the disease varies from asymptomatic carrier status to life-threatening pseudomembranous 
colitis 46. C. difficile-induced colitis is commonly treated with enteral vancomycin, fidaxomicin and 
metronidazole, but after the primary treatment approximately 30% of patients have recurrent disease 
episode 47.  
  
The major disease-causing virulence factors of C. difficile are the two large homologous clostridial 
exotoxins - toxin A (TcdA) and toxin B (TcdB). TcdA and TcdB are composed of four domains - 
glucosyl transferase domain (GTD), cysteine protease domain (CPD), pore-forming delivery domain 
and combined repetitive oligopeptide (CROP) domain.  The CROP domain of TcdA/TcdB is involved 
in recognition of the host cell receptor triggering endocytosis. The acidic environment in the 
endosome leads to a conformational change in the pore-forming delivery domain which results in 
pore formation into the endosomal membrane and translocation of GTD and CPD domains to the 
cytosolic side of the endosome. Subsequently, cytosolic inositol hexakisphosphate (IP6) activates the 
CPD domain to cleave and release GTD into the cytosol. The GTD catalyzes UDP-glucose-
consuming covalent glycosylation of  cytosolic small GTPases such as Rac1, which results in actin 
depolymerization, cell rounding, and eventually cell death 46.  
  
Bezlotoxumab is a TcdB-binding human mAb, which was identified via screening of hybridomas of  
TcdB-vaccinated HuMAb mice 48, i.e. mice that are transgenic for human and deficient for mouse 
immunoglobulin genes.  Bezlotoxumab binds to the CROP domain, and prevents TcdB from binding 
to its receptor 49, 50. Bezlotoxumab was developed by MassBiologics (MBL) in partnership with 
biopharmaceutical company Medarex. During the development of bezlotoxumab also an anti-TcdA 
human mAb (actoxumab) with similar mode of action as compared to bezlotoxumab was identified 
48, 51, but it was later shown to lack efficiency in CDI 47.   Bezlotoxumab (Zinplava®) was FDA-
approved in 2016 for the use in clinical practice to reduce recurrence of CDI in adult patients (18 
years or older) who are treated with standard of care antibiotics for C. difficile infection and are at 
high risk for CDI. Bezlotoxumab is administered via intravenous infusion [package insert - 
Zinplava® (Bezlotoxumab), Whitehouse Station, NJ, Merck & CO, Inc, 2016]. 
In preclinical cell culture-based studies bezlotoxumab, and also actoxumab, were shown to neutralize 
toxin activities of several C. difficile strains, including the epidemic ribotypes BI/NAP1/027 and 
BK/NAP7/078 52. In multiple murine models of CDI, intraperitoneally administered  actoxumab-
bezlotoxumab mixture reduced the tissue damage and inflammatory response in the gut wall 53. The 
pharmacokinetics and safety of bezlotoxumab was evaluated in two large multicenter trials 47.  The 
safety profile of bezlotoxumab was similar to that of placebo and no antibodies 
against bezlotoxumab was detected after treatment 47.  In phase II study the combination 
of actoxumab and bezlotoxumab lowered the risk of recurrent CDI among patients that also received 
standard-of-care when compared to placebo 54. Phase III trials 
for actoxumab and bezlotoxumab included two international, multicenter, double-blind, randomized 
and placebo-controlled studies (MODIFY I & MODIFY II) in which the effect 
of actoxumab and bezlotoxumab were studied on patients with primary or recurrent C. 
difficile infection 47. Primary endpoint in these studies was recurrent infection, i.e. new episode after 
initial clinical cure, within 12 weeks after infusion. In both trials the risk of recurrent CDI was 
significantly lower in the bezlotoxumab group than in the placebo group (MODIFY I: 17% vs. 28%, 
MODIFY II: 16% vs. 26%). Subgroup analyses revealed that in the subpopulations at high risk for 
recurrent infection (Age >65, history of CDI, compromised immunity, severe CDI) or for an adverse 
outcome, both groups that received bezlotoxumab had lower rate of recurrent infection than in the 
placebo group. Among high-risk patients, who were hospitalized at the time of 
infusion, bezlotoxumab decreased the rate of hospital readmission within 30 days. 
However, bezlotoxumab or actoxumab did not increase the probability on initial clinical cure. It was 
also shown that the patients that had no risk factors for recurrent CDI did not benefit from additional 
treatment with bezlotoxumab. Recently, more analysis of the MODIFY I-II data has been published, 
e.g. 55 56, that together with the real-world efficacy analysis in  clinical practice, such as in Finland 57, 
support the use of bezlotoxumab in CDI. In conclusion, bezlotoxumab has been shown to be safe and 
effective way to reduce the risk of recurrent C. difficile infection among the high-risk patients. Even 
though the cost of bezlotoxumab treatment is not negligible, cost-effectiveness analyses has shown 
to favor treatment with bezlotoxumab 58. According to ClinicalTrial.gov, there are five phase IV 
(NCT04626947, NCT03880539, NCT03937999, NCT03756454, NCT04415918) one phase III 
(NCT03182907), one phase II (NCT03829475) and two case-control studies (NCT04317963, 





Staphylococcus aureus is a Gram-positive common bacterial commensal of humans. It is also a major 
opportunistic pathogen, and the global disease burden of S. aureus infections is remarkable.  The 
severity of S. aureus infections ranges from mild skin infections, e.g. abscesses and impetigo, to 
severe and potentially life-threatening infections as pneumonia, septicaemia, osteomyelitis and 
endocarditis. Despite the appropriate antibiotic treatment, the mortality in severe infections remain 
high. The appearance of methicillin- and  vancomycin-resistant S. aureus strains is concerning as 
infections are becoming more demanding to treat 59. S. aureus produces tens of different exotoxins, 
which can be divided into three major groups - exfoliative toxins, superantigens and membrane-
disrupting toxins 7. Membrane-disrupting toxins can be further divided into four groups - α-toxin, 
hemolysin-β, leukocidins and phenol-soluble modulins (PSMs). Presumably the most renowned S. 
aureus toxin is the pore-forming α-toxin also known as Hla or α-hemolysin. It is a water-soluble 
polypeptide, secreted as a monomer by majority of clinical S. aureus strains 7. After binding to a 
receptor on the target cell surface, it quickly oligomerizes and forms a transmembrane β-barrel pore 
leading to profound cell signaling effects and  eventually to cell lysis 7. There are currently five known 
leukocidins in S. aureus strains associated with human infections - panton-valentine leukocidin (PVL 
or LukSF-PV), two γ-hemolysins (HlgAB, HlgCB), LukED and LukAB/HG 7. Leukocidins are are 
composed of two protein subunits designated as S- and F-subunits 7. The S-subunits bind to the host 
cell surface receptor leading to recruitment and dimerization of the F-subunits 7. The LukGH also 
appears to dimerize in solution 60. Oligomerization of the F-subunit dimers eventually results in the 
leukocidin pore formation 7.  
 
ASN100 was developed by Arsanis Biosciences GmbH, based on screening of high diversity yeast 
surface displayed human IgG1 libraries 60, 61.  ASN100 is composed of two fully human IgG1 mAbs, 
ASN-1 61 and ASN-2 60. ASN-1 neutralizes a-toxin and the leukocidins LukSF-PV, LukED, HlgAB 
and HlgCB via a common conformational epitope shared between a-toxin and leukocidin F-subunits 
61. Apparent mode of action is masking the phosphocholine-binding pockets of a-toxin and leukocidin 
F-subunits and thereby prevention of membrane interactions required for pore maturation 61. ASN-2 
neutralizes the fifth leukocidin, LukAB/GH 60. Interestingly, ASN-2 recognizes the S- and F-subunit 
dimeric structure, yet leading to the same mode of action than ASN-1 preventing leukocidin 
interactions with the target cells. During the first preclinical in vitro studies, ASN-1 was shown to 
inhibit a-toxin-mediated lysis of epithelial cells and leucocidin-mediated destruction of phagocytes 
and human erythrocytes 61.  The ASN-2 protected polymorphonuclear phagocytes from LukGH-
mediated lysis 60. Both ASN-1 and ASN-2 were needed to protect human leukocytes from cytotoxicity 
after exposure of culture supernatants of different S. aureus strains 62. ASN100, but also ASN-1 alone, 
was able to protect the morphology of 3D human tracheal/bronchial mucociliary epithelial tissue 
culture infected with S. aureus 62. In murine models, passive immunization with ASN-1 before 
intranasal or intravenous challenge with S. aureus, prevented lethal pneumonia and sepsis 61. Also a 
therapeutic effect was observed, when ASN-1 was administered 2 hours after intranasal challenge in 
combination with linezolid 61. In another study, the prophylactic efficacy of ASN100 in rabbit S. 
aureus pneumonia model was evaluated 63.  In this study, ASN100 was shown to increase survival in 
dose-dependent manner when given intravenously prior to intratracheal exposure of S. aureus 63. Also 
a reduced macroscopic and microscopic lung pathology and bacterial burden were observed 63. 
Pharmacokinetic analysis of bronchoalveolar lavage (BAL) fluid showed ASN100 penetration to lung 
epithelial lining fluid at 24 hours after administration with peak levels of ASN100 appearing at 48 
hours 63. 
 
The safety, tolerability and pharmacokinetics of ASN100 was evaluated in randomized, double-blind, 
phase I study with healthy volunteers 64. The subjects were randomized to receive ASN-1, ASN-2, 
ASN100 or placebo with different dosages. To assess the pharmacokinetics of ASN100 in lung 
epithelial lining fluid, BAL fluid samples were collected from twelve subjects. Study revealed that 
ASN100 and its individual components were safe and tolerable at doses up to 8000mg. No dose-
limiting toxicities were observed during the study. The most reported adverse effects were headache, 
nasopharyngitis and symptoms of gastroenteritis, but also single events of somnolence, vertigo and 
dizziness were observed. All adverse events were mild or moderate in severity and resolved without 
medical interventions. Higher dosages did not increase the risk of adverse events. ASN-1 and ASN-
2 seemed to have linear pharmacokinetics with a half-life of 20 to 36 days after intravenous 
administration. Both components were detectable in BAL fluid already at 24h or 48h and remained 
detectable at least out to day 30.  Also, the toxin neutralization activity of ASN-1 and ASN-2 was 
preserved in human sera. Anti-ASN100 antibodies were not detected in significant quantities 64. The 
effect of ASN100 for prevention of S. aureus pneumonia in mechanically ventilated patients was 
studied in multicenter, double-blind, single-dose, placebo-controlled trial (NCT02940626, study 
duration 2016 - 2018). In this study, participants (n = 155) were selected by culturing an endotracheal 
aspirate to identify those who are heavily colonized with S. aureus. Subjects were randomized to 
receive either ASN100 or placebo. The primary endpoint was to determine the proportion of patients 
which had or had not developed S. aureus pneumonia after single intravenous dose of ASN100. After 
preplanned interim analysis of 118 subjects, the data review committee informed that the study was 
unlikely to meet its primary endpoint with statistically significant difference and the trial was 
terminated. However, patients were followed for adverse effects after the trial termination. The results 
of the phase III trial have not been published, nor it is known how AS100 development pipeline is 
being continued. The mode of action of both ASN-1 and ASN-2 is blockage of the pore oligomeric 
assembly, which might be more problematic and less efficient as compared to receptor binding 
blockage.  
 
There are currently also other S. aureus exotoxin-targeted mAbs in clinical trials (Table 1). 
MEDI4893 (suvratoxumab) is a human mAb that binds  to S. aureus a-toxin, in particular to an area 
sterically preventing host cell surface receptor binding and thereby subsequent a-toxin 
oligomerization 65. In mouse model of S. aureus pneumonia, for instance, passive immunization with 
MEDI4893 was shown to decrease mortality and bacterial burden in the lungs 66. In phase I trial, 
MEDI4893 was well tolerated among subjects and no serious adverse effects were reported 67. The 
phase II trial of MEDI4893 (NCT02296320, study duration 2014 - 2018) has been conducted. No 
publications of this study have been released. AR-301, also known as Salvecin, is another mAb that 
binds and neutralizes a-toxin. No preclinical data has been published, but it is known that  AR-301 
was discovered by screening B cell repertoire of S. aureus pneumonia patient for mAbs with a-toxin 
neutralizing activity 68. Treatment of S. aureus-challenged mice with AR-301 either prophylactically 
or therapeutically, was effective 68. In a phase I/II trial, the safety and efficacy of AR-301 was 
evaluated with intensive care unit patients with severe microbiologically confirmed S. aureus 
pneumonia. The results showed that AR-301 was well-tolerated and no serious adverse effects were 
reported. In a subgroup analysis of patients with ventilator-associated bacterial pneumonia, the 
ventilation duration was shorter among patients who received AR-301 as compared to placebo 68. The 
phase III trial of AR-301 is currently in a recruiting phase (NCT03816956). 
 
Shigamabs 
Some strains of Escherichia coli, such as Shiga toxin-producing E. coli (STEC), can cause a severe 
foodborne disease. Clinical manifestations of STEC infections vary from asymptomatic carriage to 
severe hemorrhagic colitis. The most severe complication of STEC infection is hemolytic uremic 
syndrome (HUS), which is a thrombotic disorder, characterized by microvascular thrombi, 
microangiopathic hemolytic anemia, thrombocytopenia and acute renal failure. Significant portion of 
patients suffering from HUS need renal dialysis and particularly children and elderly are more 
susceptible to complications and death 69. Administration of antibiotics in these STEC infections has 
long been controversially associated with increased risk of hemolytic uremic syndrome (HUS). In a 
recent review article 70, it was concluded that the risk of HUS seems to associate to the particular 
STEC strain causing the infection and to the antibiotic class used in the treatment. Because of the 
potential negative effect of antibiotics, other alternative therapeutic agents against STEC have been 
under development and the first Shiga toxin-neutralizing mAbs were introduced in the 1980s, e.g. 71.   
 
E. coli Shiga toxins (Stx1 and Stx2), and the canonical Shigella dysenteriae Shiga toxin (Stx), are 
AB5 topology exotoxins with extremely potent cytotoxicity 72. The pentameric B-subunit mediates 
Shiga toxin binding to the host cell surface receptor globotriaosylceramide (Gb3), mainly displayed 
on the surface of endothelial cells. The receptor docking is followed by endocytosis, and retrograde 
trafficking to the Golgi and ER with subsequent release of the catalytic A-subunit from the ER into 
the cytosol. The A-subunit has  N-glycosidase enzymatic activity, i.e. it  recognizes 28s rRNA of the 
60S ribosome subunit and depurinates one specific adenine residue. This relatively small modification 
leads into blockage of protein synthesis and subsequent cell death 72.    
 
Shigamabs is a combination of two chimeric mAbs cαStx1 and cαStx2, which recognize and 
neutralize Stx1 and Stx2 73. The development pipeline is based on mouse mAbs, naimly Stx1 B-
subunit recognizing 13C4 71 and Stx2 A-subunit recognizing 11E10 74. The 13C4 mAb neutralizes 
Stx1 via blockage of Stx1-host cell receptor interaction 75, whereas  11E10 appears to alter the sub-
cellular trafficking of Stx2 76.   Thorough efficacy studies of Shigamabs in mice have been published 
73. CD-1 mice were used to evaluate the efficacy of cαStx1.  The efficacy of cαStx2 was evaluated in 
both CD-1 mice and in streptomycin-treated, orally infected mouse model of STEC infection. During 
the study, mice were either orally infected with a lethal dose of Stx2-producing STEC strain B2F1 or 
they were given intraperitoneal injection of purified Stx1 and/or Stx2 (LD50). The cαStx1, cαStx2 or 
combination of both (Shigamabs) were given intravenously either before or after infection or toxin 
administration. The results showed that cαStx1 protected CD-1 mice when given either before or after 
toxin injection. With Stx2-injected mice treated with cαStx2, the results were similar. In mice infected 
with B2F1, 0.1mg/kg dose of cαStx2 protected the mice when given at 24 or 48 hours after the 
infection. The cαStx2 was also proven to be effective when administered intramuscularly. In CD-1 
mice that were injected simultaneously with Stx1 and Stx2, both cαStx1 and cαStx2 were required to 
protect the mice. Mice that received a combination of cαStx1 and cαStx2 1 hour prior to intoxication 
had a survival rate of 70% 73. 
 
The tolerability and pharmacokinetics of cαStx2 have been evaluated in a phase I trial 77.  In this 
open-label, nonrandomized study, 17 healthy volunteers were divided in four groups to receive 
escalating doses (0.1-10mg/kg) of cαStx2 by intravenous infusion. Among the subjects, most 
common adverse effect was headache, which was reported by 52% (n=9). 35% (n=6) of the subjects 
did not report any symptoms at all during the surveillance. Two out of three volunteers who received 
highest dosage of cαStx2 (10mg/kg) reported mild joint pain, which resolved spontaneously. All three 
of them also reported mild headache. Mild and spontaneously resolving elevations in serum liver 
enzyme levels (ALT and/or AST) were also detected and one volunteer had leukopenia of 2 300 
cells/µl on day 3. However, it is not certain that these mild abnormalities in laboratory values were 
related to the infused mAb. Anti-chimeric antibodies were detected in 24% of the volunteers on day 
56, but the presence of these antibodies did not seem to have an effect on the clearance of cαStx2. 
The tolerability and pharmacokinetics of cαStx1 was evaluated in two single-center, open-label, 
nonrandomized, dose-escalation phase I studies 78.  Also, the safety of combined infusion of cαStx1 
and cαStx2 was evaluated. Subjects (n=26) were healthy adult volunteers, who received an 
intravenous infusion of cαStx1, cαStx2 or both at dose of 1mg/kg or 3mg/kg. 69% (n=18) of 
volunteers reported at least one adverse effect, but no severe adverse effects were reported among the 
subjects. The most common adverse effects were headache and mild somnolence, symptoms of upper 
respiratory tract infections and gastrointestinal inconveniences. Data analysis showed that there were 
no association between the probability of adverse effects and the cαStx dosage. Administration of 
cαStx1/cαStx2 combination did not either increase the risk of adverse effects. The pharmacokinetic 
profile of both cαStx1 and cαStx2 were similar and simultaneous infusion of both antibodies did not 
have effect on pharmacokinetics. Anti-chimeric antibodies were only detected on day 57 in one 
volunteer, who had received cαStx2. 
 
The safety, tolerability and efficacy of Shigamab was evaluated in a randomized, placebo-controlled, 
multicenter Phase II trial called SHIGATEC (NCT01252199).  The subjects (n=45) were children 
aged between 6 months to 18 years, diagnosed with Shiga toxin-producing bacterial infection and 
bloody diarrhea. The results have not been released, but the drug was mentioned in one review article 
to be well tolerated and safe according to the preliminary data 79.  However, the efficacy of Shigamabs 
in preventing HUS is still unknown. Shigamabs was developed by Thallion Pharmaceuticals Inc. in 
collaboration with LFB Biotechnologies. In 2013 it was announced that the collaboration between 
Thallion and LFB ended and all the rights of the Shigamabs program reverted to Thallion. However, 
in 2017 Sun Pharmaceutical Industries Ltd. acquired Thallion and the transaction is believed to assist 
the development of Shigamabs. At the time of the acquisition, Sun Pharma estimated that the 
commercialization of Shigamabs would take around seven to eight years. There is a possibility that 
the financial circumstances between Thallion, LFB and Sun Pharma might have an impact on the 
developmental pipeline of Shigamabs as well as data release of the clinical trials.  
 
Several other mAbs against Shiga toxins have also been developed. Most notably, the Stx2-binding 
TMA-15, also known as urtoxazumab, proceeded to phase I trial and was shown to be safe and well 
tolerated in humans 80. This developmental pipeline is based on humanized mouse mAb, VTm1.1 81, 
82, which binds to the pentameric B-subunit of Stx2. In preclinical studies, treatment with TMA-15 
up to 24 h after infection ameliorated the lethal Stx2-producing STEC strain B2F1 challenge in mice 
83. However, the urtoxazumab dosage needed to protect the STEC-infected mice appears to be  
significantly higher as compared to cαStx2 73. The efficacy of urtoxazumab has also been evaluated 
in a gnotobiotic piglet model, and the results suggest that urtoxazumab might potentially reduce post-
EHEC neurological sequelae 84. The developmental future of urtoxazumab remains unclear.  
 
hu1B7/hu11E6 cocktail  
In addition to the FDA-approved and the clinical trial mAbs (Table 1), there are a number of exotoxin-
targeted mAbs in pre-clinical development (Table 2, Suppl. Table 1). Many of these are in an early 
state. A notable difference is the developmental pipeline focused on pertussis toxin, which is the 
major virulence factor of B. pertussis 8. The Gram-negative bacterium B. pertussis is the etiological 
agent of the whooping cough, i.e. pertussis. Whooping cough is a globally distributed acute 
respiratory disease, affecting all age groups 85. However, infants and young children comprise the 
highest risk cohort, where the disease may lead to death despite hospital intensive care and use of 
antibiotics 85. Despite the global vaccine campaign pertussis remains endemic, causing outbreaks in 
many regions of the world, and the disease incidence is increasing 86. Moreover, macrolide resistant 
B. pertussis strains have been reported 87, 88. Especially young children who still lack the vaccine-
induced protection against whooping cough could benefit from pertussis toxin-neutralizing mAbs. 
The young whooping cough patients, in contrast to adults, are typically diagnosed very early and 
thereby could possess a therapeutic window to interfere with the pertussis toxin-induced pathology. 
Exposed family members of the whooping cough patients could be an additional patient group 
subjected to a prophylactic administration of pertussis toxin mAbs, possibly in combination with 
antibiotics. 
 
Humanized pertussis toxin-neutralizing monoclonal antibodies hu1B7 and hu11E6 have been 
developed 89-91, and even combined into a single bispecific mAb 92, building on the early mouse anti-
pertussis toxin antibody studies, e.g. 93. Both hu1B7 and hu11E6 antibodies, either individually or as 
a cocktail, form multivalent complexes with soluble pertussis toxin that bind the FcγRIIb receptor 
more tightly than antibodies alone 90. This indicates that the antibodies could accelerate pertussis 
toxin clearance via immune complex formation. However, hu11E6, and to some extent hu1B7, also 
prevents pertussis toxin binding to its cell surface receptor. In addition, hu1B7 appears to trap 
pertussis toxin at or near the cell surface by either interfering with endocytosis or with the early steps 
in retrograde trafficking of pertussis toxin 90. It is very encouraging that a  hu1B7/hu11E6 cocktail 
has a prophylactic and therapeutic effect in mouse (intraperitoneal route) and adult baboon 
(intravenous route) pertussis models, respectively 91. Moreover, the most recent experimentation with 
hu1B7 monotherapy (intravenous route) in an infant baboon pertussis model demonstrates a potent 
prophylactic effect 89.     
 
ANTIBODY FRAGMENTS 
Antibody fragments include the mono- and bivalent antigen-binding fragments (Fab) and F(ab')2, 
respectively, single-chain variable fragments (scFvs) and single domain antibodies, i.e. VHH 
nanobodies derived from the heavy-chain-only camelid immunoglobulins 94 (Figure 2). Antibody 
fragments can offer several advantages over the use of conventional mAbs. For example, they can be 
produced more easily, generally using microbial expression systems, which results in faster 
cultivation, higher yields, and lower production costs. Their small size also allows better tissue 
penetration and they may have reduced immunogenicity. Antibody engineering also utilizes antibody 
fragments, e.g. linking the most efficient fragments with Fc-region to engage effector functions of 
entire mAbs. Major drawback is a short serum half-life, which, however, can be engineered. The 
exotoxin-neutralizing antibody fragments are powerful prophylactic drug leads, although vast amount 
of pre-clinical data also supports their post-diagnostic therapeutic use.  
In recent years there has been substantial amount of work done towards developing antibody 
fragments that inhibit the action of bacterial exotoxins (Suppl. Table 1). These fragments include 
VHHs, Fab and F(ab’)2, scFvs and a variety of fusions of them. VHH, Fab and scFv fragments are 
often used in phage display selections and displays, and for initial characterization, but eventually 
engineered to IgG, IgG-like fusion scFv-Fcs or VHH-Fcs, as exemplified by the work done on 
staphylococcal superantigenic exotoxin B 95 and clostridial TcdB 96 and BoNT/A 97. In their recent 
work Lam et al. 98 investigated high resolution structures and neutralizing mechanisms of unique 
VHHs against BoNT/A1 and BoNT/B1 of C. botulinum. BoNT molecule is composed of a light 
chain (LC, the protease domain) and a heavy chain (HC), which is comprised of an N-terminal 
translocation domain and a C-terminal receptor-binding domain. The receptor-binding domain 
determines neuronal specificity by recognizing a polysialoganglioside, e.g. GT1b, and a 
protein receptor, i.e. synaptotagmin, Syt, for Bont/B and glycosylated synaptic vesicle protein 2, 
SV2, for BonT/A. BoNT/B has an additional hydrophobic loop in the receptor-binding 
domain, which interacts with host membrane lipids. The BoNT/B targeting VHHs were found to bind 
to the C-terminal subdomain of BoNT/B, in particular in such a way that the BoNT/B-
polysialoganglioside/Syt/lipid receptor interactions are pevented. In contrast, BoNT/A targeting 
VHHs blocked either the membrane insertion of the translocation domain or interfered with the 
unfolding of the protease domain. By connecting two VHHs with proximal epitopes 
and complementary neutralizing mechanism with flexible spacer, bifunctional VHH heterodimers 
(VHH-based neutralizing agents, VNAs) were created. These VNAs with dual epitope binding mode 
showed superior potency in mouse BoNT/A or  BoNT/B  co-intoxication assay (toxins and CHHs 
mixed prior to intraperitoneal injection)  as compared to similar VHHs that are unable to bind two 
epitopes simultaneously. Moreover, the VNAs also protected mice against BoNT/A1 and BoNT/B1 
when administered 30 or 60 min prior to toxins. The described VHH targeted epitopes are identical 
or moderately conserved between different BoNT/A and BoNT/B subtypes, respectively, so these 
VHHs likely have some affinity toward most or all BoNT/A and BoNT/B subtypes.   
 
ANTIBODY MIMETICS  
Antibody mimetics represent an alternative class of therapeutics able to overcome some of the 
limitations of mAbs, while still possessing many of their benefits, e.g. high target binding affinity and 
specificity 99. Antibody mimetics is a heterogeneous group including protein domains such as 
designed ankyrin repeat proteins (DARPins) and centyrins. Antibody mimetics are small (<20 kDa) 
single-domain scaffolds that are thermostable, highly engineerable and can be produced in 
microorganisms or even be completely synthesized chemically. As many of these scaffolds are 
derived from human proteins, they possess low immunogenicity. Owing to their small size, enhanced 
tissue penetration is also expected. Their serum half-life is short. However, this can be extended by 
engineering, e.g. with PEGylation or conjugation with serum albumin 100. 
 
Two papers have recently been published on the use of DARPins to neutralize exotoxins 101, 102. 
DARPins are derived from natural ankyrin repeat proteins, which are among the most abundant 
binding proteins found in the human genome 103. DARPins are small, single domain proteins 
(~15 kDa), consisting of three repeat modules - N-terminal capping repeat (N-cap), varying number 
of internal ankyrin repeats, and a C-terminal capping repeat (C-cap) (Figure 2). A series of monomeric 
and dimeric DARPins with potent neutralization activity for C. difficile TcdB have been developed. 
These DARPins neutralized TcdB from the laboratory strain VPI 10463 (ribotype 087), the clinical 
strain M68 (NAP9/CF/017) and the hypervirulent strain (NAP1/BI/027). The 
monomeric DARPins against TcdB interfered with the interaction between TcdB and its receptors 
chondroitin sulfate proteoglycan 4 (CSPG4) and Frizzled receptor 2 (FZD2), respectively, by binding 
to the delivery domain of TcdB. Dimers were generated by combining the monomers, which 
interfered with the CSPG4 and FZD2 receptor docking.In vitro studies showed that the best DARPins, 
the dimeric DLD-4 against the TcdB from strains VPI 10463 and M68, and monomeric D16 against 
the hypervirulent strain (ribotype 027) TcdB had superior TcdB-neutralization potencies as compared 
to the FDA-approved mAb bezlotoxumab. In vivo efficacy of the dimeric DLD-4 has also been 
studied in two mouse models, intraperitoneal injection and cecum injection models, 
against TcdB challenge. Significant increase in the mouse survival with intraperitoneal injection of 
pre-incubated mix of TcdB and DLD-4 was monitored, indicating that DLD-4 possesses significant 
toxin-neutralization ability in vivo.  However, only a minor survival advantage was observed with the 
cecum injection model in mice receiving combination of TcdB and DLD-4 compared to TcdB alone. 
This was due to the unexpectedly poor resistance of DLD-4 against the protease activity of gut trypsin 
and chymotrypsin. This shortcoming might be overcome by obtaining protease-stable variants of 
this DARPin with second-generation engineering. It remains unclear whether the DARPins would 
attenuate TcdB-induced symptoms after a systemic TcdB exposure.  
 
Centyrins that neutralize the bicomponent leukocidins PVL, HlgAB, HlgCB, LukED, 
and LukAB of S. aureus have been identified 104.  Centyrins are small (~10 kDa) globular proteins 
derived from a consensus sequence of the 15 fibronectin type III (FN3)-binding domains of the 
human tenascin-C protein 105, 106. These centyrins blocked binding of bicomponent leukocidins to 
their host cell surface receptors. Some of the centyrins exhibited cross-reactive properties 
targeting leukocidins that share strong amino acid sequence conservation between their subunits, 
e.g. HlgCB and LukSF-PV. Centyrins also protected human phagocytes from toxin-mediated killing. 
In murine models of LukED or HlgAB intoxication, centyrins and centyrin-serum albumin fusion 
constructs premixed with toxins before intravenous administration or centyrins given 
prophylactically before toxin administration were shown to protect the mice. Centyrin-serum albumin 
fusion constructs also markedly improved survival and reduction of bacterial burdens when given 4 
hours after intravenous infection with highly virulent MRSA. With further engineering, these biologic 
agents with toxin neutralizing activity could have a potential clinical utility in the treatment and 
prevention of serious staphylococcal infections. 
 
RECEPTOR ANALOGS AND NEUTRALIZING SCAFFOLDS   
Receptor analogs and neutralizing scaffolds is a heterogeneous group of exotoxin-targeted drug leads. 
They prevent the interaction of exotoxins with their host cell receptor structures, i.e. lipids, 
carbohydrates or proteins, via molecular mimicry or they reduce the bio-availability of the soluble 
forms of exotoxins via sequestration. Obvious benefits include generally good tolerability and long 
half-lifes as many of these are based on natural host cell surface structures. These modalities include 
some of the most early attempts to develop exotoxin-neutralizing strategies. However, recent 
interesting developments have emerged, e.g. combinations of multiple modes-of-action into a single 
product. As for now, three development pipelines have entered clinical trials, SYNSORB-Pk, 
Tolevamer and CAL-02 (Table 1).   
 
SYNSORB-Pk is a polymer with the Shiga toxin host cell surface receptor Gb3 trisaccharide moiety 
covalently linked to silicon dioxide particles via a defined linker 107. Orally administrated 
SYNSORB-Pk was safely tolerated by healthy adult volunteers in a phase I study without any 
evidence of toxicity 107. In the same study, SYNSORB-Pk remained active upon passage through the 
gastrointestinal tract, i.e. it neutralized Shiga toxin in ETEC-positive stool samples from patients with 
hemolytic uremic syndrome (HUS) or hemorrhagic colitis 107. However, a multicenter double-blind 
phase III clinical trial demonstrated that SYNSORB-Pk was ineffective at reducing the severity of 
diarrhea-associated HUS in pediatric patients 108. There are a number of possibilities to explain the 
negative outcome, one being simply the lack of efficiency. However, only third  of the enrolled 
diarrhea-associated HUS patients had viable STEC or free Shiga toxins in their stool samples 108. The 
authors proposed that the SYNSORB-Pk intervention might have started too late to have a therapeutic 
effect, i.e. Shiga toxin had already entered the circulation. The SYNSORB-Pk development pipeline 
has been on apparent hold since the discouraging phase III clinical trial was conducted 20 years ago.  
 
Tolevamer, formerly known as GT160-246 and GT267-004, is a high molecular weight (≥400 kDa), 
soluble linear polymer of styrene sulfonate that binds and neutralizes C. difficile toxins TcdA and 
TcdB  in vitro and in vivo 109-111. The exact binding mode is not known. The GT160-246 version was 
found to be non-inferior, i.e. not worse, to vancomycin in mild to moderate CDI in a phase II clinical 
trial 112.  The GT160-246 version was well tolerated in this promising phase II trial, but a common 
side effect was hypokalemia 112. Therefore, a new oral solution formulation with a mixed potassium 
sodium salt of Tolevamer (GT267-004) was developed 113. The GT267-004 version demonstrated 
lower hypokalemia side-effects and was well-tolerated in a phase I trial 113. However, the GT267-004 
version was found to be inferior, i.e. worse, to standard antibiotic therapy for CDI conducted either 
with vancomycin or metronidazole in two multinational phase III trials 114. This discouraging result 
could, in part, be explained by the fact that Tolevamer interacts less tightly with TcdB as compared 
to TcdA in vitro 110. Phase III clinical trials with a different drug modality, intravenously-
administrated mAbs, demonstrated efficacy only with TcdB neutralization 47  (see more above). 
Animal experimentation and prevalence of TcdA- and TcdB-encoding genes in clinical C. difficile 
isolates also indicates dominance of TcdB in disease pathology 46. Tolevamer development pipeline 
has been on apparent hold since the discouraging phase III clinical trials were conducted 15 years 
ago. 
 
The exotoxin-targeted drug development pipeline contains a plethora of other approaches to 
neutralize exotoxins with receptor analogs and neutralizing scaffolds (Suppl. Table 1), as exemplified 
by the work on Shiga toxins.  The Daisy 115 , Starfish  116 and Super Twig 117, 118  concepts are 
polyvalent Shiga toxin carbohydrate receptor analogs, which have been efficient in pre-clinical in 
vitro and in vivo experimentation. However, clinical trials have not been conducted on these early 
drug candidates. An interesting variant concept of receptor analogs, which also acts as an efficient 
neutralizing scaffold, relies on the use of a recombinant bacterium that expresses a mimic of the Shiga 
toxin  receptor globotriaosyl ceramide (Gb3) on its surface 119. This engineered bacterium was also 
effective in vivo, protecting mice from otherwise fatal STEC infection 119. This concept was recently 
upgraded via the development of Gb3 receptor mimic bacterial ghosts (BGs) 120.  BGs are empty, 
non-living bacterial envelopes of Gram-negative bacteria that are not classified as genetically 
modified organisms, and thereby could remove barriers in the development of bacterium-displayed 
Gb3 receptors towards clinical use 120.  Recently, nanoparticles functionalized with lipids, receptors, 
receptor fragment or peptides have been developed as one type of neutralizing scaffolds. For example, 
calcium phosphate nanoparticles loaded with peptides derived from the CTLD4 domain of the human 
mannose receptor, MRC-1, that interacts with the conserved cholesterol-binding loop of cholesterol 
dependent cytolysin (CDCs) 121, 122 were shown to be able to improve survival and bacterial clearance 
in in vivo models of pneumococcal infection 121.  
 
Many toxins, especially many cytolysin (cholesterol dependent cytolysins, CDCs), bind preferentially 
to cholesterol-containing membranes. By using membrane mimicking neutralizing scaffolds, such as 
nanoparticles coated with lipids, liposomes containing cholesterol at higher than physiological levels 
123, exosomes 124 or so called biomimetic nanosponges composed of a red blood cell membrane 
(RBCM) fused to a polymer nanoparticle core, it is possible to inhibit wide variety of exotoxins from 
binding to the host cell membrane 125-128. Nanosponges have the same repertoire of cell membrane 
receptors as their host cell, so they can act as non-specific toxin decoy strategy with a broad ability 
to sequester and neutralize various bacterial exotoxins. One application of these nanosponges is to 
include an antibiotic 127, 128  or other bacterium-targeting molecule 129 into the nanoparticle core. When 
the exotoxins bind and destroy the RBCM coating, the antibacterial compound trapped inside the 
nanoparticle is released. These approaches aim for more targeted delivery of the antibiotic by 
releasing it in the site of infection. Whole red blood cells can also be used as scaffolds to prolong the 
circulatory half-life of exotoxin-neutralizing molecules. Genetically engineered red blood cells 
expressing chimeric proteins of camelid VHHs with blood group antigens Glycophorin A or Kell 
were shown to confer long-term protection against botulinum neurotoxin A when transfused to mice 
exposed to highly lethal doses of BoNT/A 130.  These recent developments exemplify the concept 
where different drug modalities are being combined to a single therapeutic, to increase efficiency and 
targeting capability. One of the exciting new approaches relies on the use of liposomes to treat 
bacterial infections.  CAL-02 consists of a mixture of liposomes that create artificially large and stable 
liquid-ordered lipid microdomains and function as docking sites for a large range of bacterial toxins 
131. CAL-02 recently entered phase I trial in severe pneumococcal pneumonia , and it was shown to 
possess a promising safety profile and tolerability when administered by infusion 131. 
 
DOMINANT NEGATIVE MUTANTS 
Several exotoxins, in particular membrane-disrupting toxins such as a-toxin of S. aureus 132 require 
assembly and oligomerization at the host cell surface in order to execute their cytotoxic effector 
activities. While deciphering the mechanisms by which leukocidin LukED, another pore-forming 
exotoxin of S. aureus, targets and kills host cells, short glycine-rich motifs within the stem domains 
of LukE and LukeD were identified as necessary structural elements 133. Remarkably, mutant 
leukocidin subunits lacking these motifs behaved as dominant-negative toxins and neutralized the 
cytolytic activity of wild-type leukocidins in vitro in cell cultures 133. The mutant leukocidin subunits 
appeared to bind on the host cell surface receptors, and also were able to interact with the wild-type 
leucocidin subunits 133. The data implies that mechanistically the dominant negative mutant subunits 
and wild-type subunits of leukocidins hetero-oligomerize but assemble into a defective pore complex, 
thereby inhibiting toxicity. It is interesting that intravenous administration of dominant negative 
mutants had a prophylactic and therapeutic effect in mouse models of intravenous leukocidin 
challenge and S. aureus infection, respectively 133. 
  
The above study on S. aureus leukocidins is preceded by other similar studies proposing the use of 
dominant negative mutants to prevent the functions of membrane-disrupting toxins, e.g. on 
Clostridium perfringens e-toxin 134, Helicobacter pylori VacA 135 and Bacillus anthracis anthrax-
toxin 136-138. These examples imply that the use of dominant-negative mutants is a feasible strategy to 
neutralize multimeric membrane-disrupting toxins. However, efficient and broad development of this 
drug modality would require an in-depth high-resolution structural knowledge, allowing rational 
mutant design, that is not currently available for many membrane-disrupting toxins. Also, the number 
of mutations that inactivate the toxins is expected to be substantially greater than the number of 
mutations that lead to a dominant-negative phenotype. In the end, this means more screening work 
and slower progress. One additional potential problem, based on the recent S. aureus leukocidin work 
133, appears to be the short half-lifes of the dominant-negative mutants. Intravenously administrated 
dominant negative mutants were protective if they were given no more than 5 hours before the wild-
type leukocidin challenge 133. Parallel experiments done with S. aureus infections also indicated 
problems with the half-lifes 133. As for now, it appears that the dominant negative mutants of 
exotoxins remain as very useful basic research tools, rather than efficient emplates for drug 
development. However,  one variant of the dominant negative approach is the use of exotoxin-derived 
peptides, which destabilize the exotoxin structure and thereby inhibit the cellular toxicity, as 
exemplified with TcdB of C. difficile 139. These kinds of peptides are expected to have better 
pharmacokinetic properties as compared to full length protein subunits.   
 
SMALL MOLECULES  
Small molecules have been the traditional basis for drug development and almost two-thirds of 
approved medicines are either naturally derived or synthetic small molecules 140. Small molecule 
drugs typically have no more than 100 atoms, and they are no bigger than 1000 g/mol or 1 kDa in 
size. Small molecules have distinct advantages as therapeutics. Due to their small size, small 
molecules penetrate tissues efficiently, and may also enter the cell allowing effective targeting of 
cytosolic processes. Most can be formulated and optimized for oral administration, allowing 
absorption into the bloodstream and thereby access to the whole body. Due to the possibility to 
produce small molecules via chemical synthesis, the production costs are typically lower as compared 
to other modalities, e.g. mAbs. Small molecules can be designed to engage biological targets, mostly 
proteins, by various modes of action with high resolution structure-based rational drug design 
approaches. These include binding to and inhibition of enzyme active sites, binding to allosteric sites 
influencing enzyme activities and structural transitions, and binding to regions of proteins mediating 
interactions with other proteins, i.e. protein-protein interaction (PPI) inhibitors. In addition, high-
throughput screening with small molecule compound or fragment libraries using cell-based or in vitro 
biochemical assays allows efficient identification of bioactive hit compounds.   
 
Small molecules that prevent the cell binding of exotoxins have been identified both using un-biased 
high-content screening exercises as well as high resolution structure-based rational drug design. One 
notable study utilized an imaging-based phenotypic screen to identify small molecules that protected 
the cells from C. difficile TcdB-induced morphological alterations 141.  The screen lead into 
identification of methyl cholate, a bile acid derivative. Subsequent validation experiments on binding 
with differential scanning fluorimetry (DSF) demonstrated that the thermal stability of TcdB was 
strongly increased by methyl cholate 141. At cellular level, methyl cholate lowered the amounts of 
cell-associated TcdB 141. In an in vitro biochemical assay, methyl cholate supressed the IP6-induced 
auto-processing activity of TcdB. The data indicates that methyl cholate directly binds to TcdB and 
induces a conformational change affecting receptor binding and autoprocessing activity. A structure 
activity relationship (SAR) study will be very interesting to understand the methyl cholate mode of 
action.  
 
The cytolytic process of pore-forming toxins of S. aureus, α-toxin and bicomponent leukotoxins, 
begins with the binding of soluble toxin monomers to a cell surface receptor, where they associate to 
form a nonlytic, oligomeric pre-pore structure 7. Finally, the translocation of the prestem regions 
across the membrane results in the bilayer-spanning β-barrel pore structure and consequent membrane 
permeabilization and cell lysis7. In a recent study, crystal structures revealed evolutionarily conserved 
phosphatidylcholine-binding mechanisms for LukED, PVL and α-toxin 142. A phosphatidylcholine 
mimetic compound n-tetradecylphosphocholine (C14PC) was found to able to significantly reduce 
the lytic activity of these toxins in vitro. In addition to broad-spectrum inhibitory action 
towards LukED, PVL, and α-toxin, C14PC also has low production costs, and thus it might serve as 
starting-point in the development of agents that reduce the virulence of S. aureus infection 
prophylactically and therapeutically. The C14P compound is also expected to be well-tolerated by 
humans, as similarly structured drug miltefosine (hexadecylophosphocline C16P, also known 
as Impavido) is FDA-approved as an oral antiparasitic for the treatment of leishmaniasis 143.   
 
DRUGGABLE STEP II - INTRACELLULAR MATURATION  
Intracellular-targeting toxins such as pertussis toxin and anthrax toxin undergo complex maturation 
process, often involving complete retrograde trafficking from the endosome to Golgi and ER followed 
by effector subunit release into the cytosol. Exotoxins may rely on their auto-processing properties, 
e.g. TcdB of C. difficile, or be dependent on oligomerization in order to deliver their enzymatic cargo 
into the cytosol, e.g. anthrax toxin. Antibodies, antibody fragments and small molecules have been 
identified that interfere with these processes.  
 
MONOCLONAL ANTIBODIES 
Large amounts of exotoxin-neutralizing mAbs haven identified (see above, Table 1, Suppl. Table 1). 
Depending on the binding epitope, these mAbs may not necessarily prevent exotoxin binding to the 
host cell surface receptor, but act more downstream in the functional pathway of exotoxins (Figure 
1). The same applies for the antibody-fragments. The downstream effect is exemplified in the case of 
developmental pipeline with humanized mAbs PA-50 and PA-41 targeting C. difficile TcdA and 
TcdB, respectively 144. The humanized mAbs PA-50 and PA-41 efficiently neutralized TcdA/TcdB 
in cell culture experiments, and demonstrated efficacy in hamster model for CDI 144.  The PA50 mAb 
was shown to bind to multiple sites on the TcdA C-terminal combined repetitive oligopeptide (CROP) 
domain, based on high resolution structural data 145. Binding of TcdA to the host cell surface was 
prevented by PA50 mAb indicating that receptor blockade is the mode of action by which PA50 
neutralizes TcdA.145 This is the same mode-of-action how the clinical use bezlotoxoumab (anti-TcdB 
mAb) and aclotoxumab (anti-TcdA mAb) appear to be working 48-51. In contrast, an entirely different 
neutralization mechanism was shown for PA41, the TcdB specific mAb, based on high resolution 
structural data 146. The PA41 mAb recognizes a single, highly conserved epitope on the TcdB 
glucosyltransferase domain 146.  The PA41 mAb does not block TcdB from binding or entering the 
host cell via endocytosis 146. The PA41 mAb rather prevents the translocation of the 
glucosyltransferase enzymatic cargo from the endosome into the host cell cytosol 146. Alternative 
mode of actions have also been reported for anthrax toxin-neutralizing mAbs.  Following endocytosis 
of the prepore-EF/LF complex, an acid-driven prepore-to-pore conversion occurs, thus promoting the 
entry of EF/LF into the cytosol, where they exert their toxic effects  147. The cAb29, an anti-PA 
antibody, appeared to prevent the PA-formed pre-pore to undergo conformational changes into the 
mature pore structure in the acidic endosomal compartment and therefore prevented the toxin cargo 
delivery into the cytosol 147. This mode of action is in contrast to obiltoxaximab and raxibacumab, 
which recognize the receptor-binding region of PA 35, 36 and thereby block PA-host cell surface 
interactions. Moreover, intracellular maturation blocking mAbs have been identified in the Shiga 
toxin-focused drug development efforts, e.g. also in the Shigamabs developmental pipeline (see 
above). For example, human mAb 5C12, which binds to the catalytic A-subunit, did not interfere with 
the cell surface binding of Stx-2 148. In contrast, 5C12 blocked the retrograde transport of Stx-2 into 
the Golgi and ER, preventing the entry of A-subunit into the cytosol 148. The 5C12 study demonstrates 
an important point in respect of the use of exotoxin-neutralizing mAbs. The 5C12 was able to bind to 
the already cell-bound Stx-2 148. This potentially extends the therapeutic window as compared to 
mAbs, which prevent the cell binding of exotoxins.   
 
SMALL MOLECULES 
Interesting development pipelines have been focused on small molecules that interfere with the 
intracellular maturation of exotoxins, in particular their auto-processing activity.  Ebselen (2-phenyl-
1,2-benzoselenazol-3-one) is a lipid soluble membrane-penetrating organoselenium compound 149. 
Ebselen has generic antioxidant properties, e.g. it  catalyzes the reduction of reactive oxygen species 
(ROS) in a manner similar to glutathione peroxidase 149. Ebselen also  readily and covalently modify 
cysteine residues 149. Ebselen was identified as an inhibitor of the auto-processing cysteine protease 
domain (CPD) of TcdB in an in vitro fluorescence polarization high throughput screen 150.  Follow-
up studies demonstrated that Ebselen also inhibited auto-processing of TcdA 150. Mechanistically, it 
was shown that Ebselen covalently modified the CPD domain of TcdA/TdB at cysteine residues 
leading to suppression of cysteine protease activity 150.  Ebselen was also identified  independently 
as TcdB inhibitor in a high throughput cell phenotypic screen  141. The authors worked out on the 
mode of action in vitro, and proposed, in contrast to 150, 151,  that Ebselen acts on the 
glycosyltransferase activity of TcdB preventing glycosylation of the small GTPase Rac1152.  The 
inhibitory action on TcdB appeared to be indirect, acting via Ebselen-mediated modification of 
cysteine residues on Rac1152. The initial screening studies showed that Ebselen protected cells and 
mice against TcdA/TcdB-mediated killing and improved histopathology in a murine CDI model 141, 
150. Recently, animal experimentation was extended to show that Ebselen, as a monotherapy, reduces 
recurrence rates and decreases the severity of colitis in animal models of CDI  153. Moreover, Ebselen 
has already advanced to phase III clinical trials in diseases unrelated to CDI, e.g. diabetes 
(NCT00762671). Therefore, Ebselen appears as a well-tolerated drug candidate to treat CDI. As for 
now, it remains unknown to what extent Ebselen functions via its generic anti-inflammatory 
properties and to what extent via its anti-TcdA/TcdB functions. Pan-reactivity with cysteine residues 
is a concerning fact, but the exotoxin neutralization potency itself, not the detailed mechanism of 
action, is perhaps of more practical interest.  
 
The multifunctional auto-processing repeats-in-toxins (MARTX) toxin, e.g. in V. cholerae, also relies 
on proteolytic auto-processing for cellular activity 154. Similar to the CPD domains of clostridial 
toxins TcdA and TcdB,  MARTX toxin of V. cholerae is activated by IP6 154. Covalent cysteine 
protease inhibitors were identified, which interfered with the MARTX toxin auto-processing 154. 
Notably, a high resolution structure CPD in complex with the aza-leucine epoxide inhibitor JCP598 
was determined 154. The overall structure of inhibitor-bound, activated CPD is nearly identical to the 
activated CPD 154. The data indicates that the inhibitor docks into the active site cleft created upon 
binding of IP6 to the CPD 154. Similar kind of a study has been published on covalent C. difficile CPD 
inhibitors 155, building in part on the work on V. cholerae MARTX toxin 154. High resolution structural 
information was obtained of the inhibitor-CPD complex and some of the analyzed small molecules 
were potent in living cells to inhibit TcdB functions 155. It remains to be determined if the specificity 
of these particular covalent protease inhibitors for MARTX and TcdA/TcdB toxins is high enough at 
the cellular and whole body level to allow further development as a drug lead.   
 
A novel therapeutic paradigm explored the possibility to target the autoproteolysis activity 
of TcdB by triggering its IP6-induced auto-proteolysis in the gut lumen 156.   To reach this goal, 
a gain-of-function small molecules, IP6 analogues were synthetized by progressively replacing the 
IP6 phosphate groups with sulfate groups. This was done in order to reduce the susceptibility of 
IP6 to complexation at physiological calcium concentrations at colon lumen, while maintaining the 
uniquely high charge density that mediates its interaction with TcdB. Partial replacement of 
phosphates by sulfates and thiophosphates resulted in analogs (IP2S4, IT2S4) capable of 
inducing TcdB cleavage at micromolar concentrations in the presence of calcium 156.  In mouse model 
of colitis, oral administration of IP2S4, was shown to attenuate the symptoms. Furthermore, treatment 
with the thiophosphate analog IT2S4, which has improved stability toward inositol phosphatase 
enzymes that may be present in the gut lumen, rescued mice in the acute CDI model 156. Taken 
together, pharmaceutical targeting of the auto-proteolytic activity of exotoxins appears as a very 
promising therapeutic strategy. 
 
DRUGGABLE STEP III - CYTOSOLIC EFFECTOR FUNCTIONS 
This step in the functional pathway of exotoxins refers to the point where the exotoxin, in particular 
its effector domain, has been released from the endosome or the Golgi/ER compartment into the 
cytosol. Some exotoxins also gain access into the cytosol straight from the plasma membrane. For 
instance, NAD+ glycohydrolase (SPN) of Streptococcus pyogenes utilizes the multimeric pore 
structure created by another exotoxin of S. pyogenes, streptolysin S (SLO), at the host cell membrane 
157. Also, the bifunctional hemolysin/adenylate cyclase (CyaA) of Bordetella pertussis first binds to 
the surface, and subsequently inserts its cyclic AMP (cAMP)-generating catalytic domain into the 
cytosolic side of the plasma membrane 158.  
 
SMALL MOLECULES 
There have been a number of attempts to develop small molecules inhibiting the cytosolic effector 
functions of exotoxins. Major advantage with these compounds would be that they are capable of 
preventing exotoxin functions after the exotoxin has been internalized. This mode of action should 
open up wider practical possibilities for the drugs, in particular in therapeutic use. One notable high-
content screening exercise was undertaken to identify inhibitors of the glucosyltransferase activity of 
C. difficile TcdB 159.  The compounds were screened utilizing a 1536-well fluorescence polarization 
assay for UDP-glucose hydrolysis activity by the C-terminal glucosyltransferase domain of TcdB 159. 
Multiple hits were identified from diverse six million-member compound collection 159. Hit-to-lead 
optimization efforts centered around a novel series of benzodiazepinedione-based inhibitors 159, 160. 
Optimized compounds have demonstrated good pharmacokinetic profiles in mouse and hamster and 
have been efficacious in multiple cell culture and animal models of C. difficile infection upon oral 
dosing 159, 161. We have recently identified small molecules inhibiting the ADP-ribosyltransferase 
(ART) activity of pertussis toxin 162. We developed an in vitro high throughput-compatible assay to 
quantify NAD+ consumption during PtxS1-catalyzed ADP-ribosylation of Gαi in vitro. Two 
inhibitory compounds (NSC228155 and NSC29193) with low micromolar IC50-values were 
identified in the in vitro NAD+ consumption assay via screening of a focused compound library 
containing approximately 2000 small molecules. These compounds were also potent in an 
independent in vitro assay monitoring conjugation of ADP-ribose to Gi. Moreover, the membrane 
permeable NSC228155 inhibited the pertussis AB5 holotoxin-catalyzed ADP-ribosylation of Gi in 
living human cells with a low micromolar IC50-value. Although NSC228155 was well-tolerated at 
these low micromolar inhibitory concentrations, we witnessed significant cellular toxicity with 
NSC228155 upon our titration analyses. We currently employ medicinal chemistry efforts including 
molecular modeling and protein crystallography in an attempt to design less toxic NCS228155 
analogs with additionally increased potency and specificity.  
 
In addition to B. pertussis, ART-toxins are key virulence factors of several pathogens such as C. 
diphthteria (diphtheria toxin), V. cholera (cholera toxin) and E. coli (heat-labile enterotoxin) 14. 
Selective targeting and inhibition of their ADP-ribosyltranferase activity holds promise to interfere 
with disease pathology. Hit compounds inhibiting P. aeruginosa ExoA-induced cytotoxicity in yeast 
and mammalian cell-based assays in vitro have been identified 163. Virtual screening on the crystal 
structure of a closely related cholic toxin of V. cholera was primarily used to design the screened 
compound library 164.  Hit compounds for ART-toxins of B. sphaericus, C. difficile, and C. botulinum 
were found via in vitro screening of kinase inhibitors, which are typically adenosine mimics and 
thereby chemically related to NAD+ 165. Bisubstrate analogs mimicking the nicotinamide portion of 
NAD+ and arginine residue of the target host cell protein have also been developed to inhibit cholera 
toxin 166. In addition, structures of NAD+- or hit compound-bound ART-toxins have allowed 
computational analyses to understand the binding modes and to provide rational ideas for further 
improvements, as in the case of cholix-toxin of V. cholera 163, 167. However, despite the recent 
advancements, a rationally designed small molecule targeting bacterial ART-toxins has yet to reach 
preclinical animal experimentation. 
 
Small molecules that prevent the cytosolic effector functions have also been identified by cell-based 
screening exercises. The naturally occurring flavonoid phloretin was identified as a compound 
protecting cells from both C. difficile TcdA- and TcdB-induced cell rounding 141. Subsequent 
validation experiments demonstrated that phloretin was a direct inhibitor of the toxin GTD domains 
of both TcdA and TcdB rounding 141. The authors conducted a secondary focused library screening  
with flavonoid compounds, and identified two potent analogs of phloretin 141. Phloretin appears to 
act as a non-competitive inhibitor and thereby with a probable allosteric action. The authors argued 
that this mode of action may offer high selectivity and specificity over other enzymes that utilize the 
same substrate, in this case UDP-glucose 141. This highlights the drawback, for example, in our own 
ADP-ribosyltransferase studies where we aimed to identify competitive small molecules binding to 
the NAD+ binding active site of pertussis toxin 162. These compounds may also interact with the 
plethora of other NAD+ binding proteins in the cell, such as members of the poly(ADP-ribose)-
polymerase (PARP) protein family 168. It remains to be studied whether or not these off-target-effects 
are a concern.  
 
CONCLUSIONS AND FUTURE PERSPECTIVES 
The pre-clinical, clinical trial and real-world clinical data demonstrate that exotoxin-targeted 
antivirulence therapy can be effective, notably exemplified by the toxin B (TcdB)-neutralizing 
bezlotoxumab to prophylactically reduce recurrence of C. difficile infections. Antivirulence drugs 
have potential as stand-alone prophylactic and therapeutic pharmaceuticals, but they also may 
complement the use of antibiotics, e.g. to allow lowering of the dosage of antibiotics. Three main 
reasons are driving the rapid expansion of research on antivirulence therapy. First of all, widespread 
antibiotic resistance calls for the development of new alternative ways to treat bacterial infections. 
Secondly, awareness of the physiological importance of microbiota forces us to consider treatment 
of bacterial infections with more focused pathogen-specific pharmaceuticals. Thirdly, decades of 
basic research using various in vitro assays, cell and tissue culture models and animal experimentation 
have created an in-depth view on bacterial virulence factors as potential drug targets.  
There are a number of challenges to overcome, in particular in the therapeutic use of exotoxin-targeted 
drug modalities. The therapeutic window is one major concern. Typically, upon clinical suspicion of 
bacterial infection, patients receive empiric antimicrobial therapy, in many cases broad-spectrum, 
before we have the diagnostic data. Antivirulence therapy is pathogen-specific, and thereby requires 
a diagnostic finding to be effective. When such data becomes available, can we still interfere with the 
disease pathology? The answer appears to be yes, at least based on pre-clinical data with animal 
experiments on exotoxin-targeted drug modalities. Perhaps the therapeutic window could be extended 
by directing more pre-clinical development to modalities, which can also act inside the host cell such 
as small molecules. This modality has the additional benefit that most small molecules can be 
formulated and optimized for oral administration. This would help the clinical use, including self-
medication, as compared to modalities requiring more laborious administration techniques, such as 
infusion with mAbs. The wider applicability of antivirulence drugs in clinic, in analogy to antibiotics, 
is another major concern, which also affects the developmental interest of the big pharma. Exotoxins 
do have a significant and sometimes the primary role as the disease-causing virulence factor, but 
bacterial virulence is still a multifactorial process. Dominant virulence factors are not even know for 
many important bacterial pathogens. Perhaps cocktails of different virulence factor-targeting drugs 
against specific bacterial pathogens could be developed, although this would increase the 
developmental costs and the length of the developmental pipelines. Good thing is that there is active 
basic research on exotoxins and other bacterial virulence factors. New virulence factors are being 
identified. The knowledge on virulence factors prevalence and variability in clinic and nature 
increases. The high resolution structural understanding of the functional  properties of virulence 
factors is getting better. Taken together, although important progress has been made in the 
development of exotoxin-targeted drug modalities, and antivirulence therapy, significant work is still 
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Figure 1. (title on next page) 
Figure 1. Exotoxin mode of functions and main druggable steps in the functional pathway of 
exotoxins. Exotoxins are bacterial proteins that are either actively secreted from the bacterium in an 
energy-dependent process or they become soluble upon bacterial lysis. Exotoxins recognize the host 
cell surface via specific receptor structures composed of proteins, lipids or carbohydrates. Exotoxins 
have potent host modulating activities either at the host cell surface or inside the host cell. 
Intracellular-targeting toxins undergo complex maturation process, often involving complete 
retrograde trafficking process from the endosome to Golgi and ER followed by effector subunit 
release into the cytosol. Exotoxins are typically classified in three different types, i.e. Type I - 
superantigens, Type II - membrane-disrupting toxins (pore-forming toxins, lipid-modifying enzymes 
and detergent-like peptides), and Type III - intracellular-targeting toxins. Some overlap exists 
between these three types, e.g. listeriolysin of Listeria monocytogenes forms pores in the endosomal 
membranes. TSST-1, toxic shock syndrome toxin; PTX, pertussis toxin; TcdB, toxin B; Stx1/2, Shiga 
toxin 1/2; CNF1, necrotizing factor 1; TT, tetanus toxin; TNT, tuberculosis necrotizing toxin; CyaA, 
























Figure 2. Exotoxin-targeted drug modalities. Schematic representations of the different exotoxin-
targeted drug modalities that are under pre-clinical and clinical development or use. The modalities 
and their examples are not drawn in scale. A) Monoclonal antibodies (mAbs). The mAbs  have 
several advantages in exotoxin-targeting such as high specificity, long in vivo half-life in circulation 
and good tolerability. All currently FDA-approved exotoxin-neutralizing drugs are mAbs (Table 1).  
B) Antibody fragments.  Antibody fragments can be produced more easily, as compared to mAbs, 
which results in faster cultivation, higher yields, and lower production costs. Their small size also 
allows better tissue penetration and they may have reduced immunogenicity. Antibody engineering 
also utilizes antibody fragments, e.g. linking the most efficient fragments with Fc-region to engage 
effector functions of entire mAbs. C) Antibody mimetics. Antibody mimetics, such as DARPins, are 
diverse group of single-domain protein scaffolds that are thermostable, highly engineerable and can 
be produced in microorganisms or even be completely synthesized chemically. D) Receptor analogs 
and neutralizing scaffolds. This is a very heterogeneous group of drug candidates, including 
exotoxin-binding polymeric molecules, e.g. Tolevamer, polyvalent exotoxin receptor analogs, e.g. 
SYNSORB-Pk, and various liposome-, exosome-, nanoparticle- or even bacteria-based carrier 
particles having exotoxin-absorbing macromolecules. E) Dominant negative subunits. Exotoxins 
that functionally rely on multimerization, such as pore-forming toxins, can be trapped to a pre-mature 
state by dominant negative subunits. One flavor of this approach utilizes peptides derived from the 
exotoxin subunits that interfere with the assembly process. F) Small molecules. Small molecules 
have been the traditional basis for drug development. Due to their small size, small molecules 
penetrate tissues efficiently, and may also enter the cell allowing effective targeting of intracellular 
processes, such as the enzymatic functions of exotoxins (Figure 1). As for now, however, a limited 
amount of small molecule high-throughput screening studies have been conducted on exotoxins. 
Example taken from our recent in vitro screening exercise to identify inhibitors of the ADP-
ribosyltransferase activity of pertussis toxin 162. Refer to the main text, Table 1 and Suppl. Table 1 








Table 1. Exotoxin-targeted drugs that are either FDA-approved or that have entered clinical 
trials.  Clinical trial data based on ClinicalTrials.gov database as literature searches, as of 18th march 
2021 (https://www.clinicaltrials.gov). Ebselen trials have been conducted in diseases other than C. 
difficile infections, e.g. diabetes phase III trial NCT00762671.    
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